Exploring the Therapeutic Potential of Clusterin in a Preclinical Model of Alzheimer’s Disease

2022, 2023

This proposal is aimed at exploring a protein called Clusterin, a significant risk factor for Alzheimer’s disease (AD) that is highly expressed in the brain of patients with this condition. Our data presented here suggest that Clusterin inhibits differentiation of cells that can repair damage of the protective neuronal sheet called myelin, leading to our hypothesis that Clusterin overexpression directly contributes to Alzheimer’s disease. Our research proposed in this application could offer new solutions to promote neuroprotection and delay the irreversible cognitive decline in the AD brain.

Funding to Date



Studies of Novel AD Genes, Translational


Alban Gaultier, Ph.D.